Display options
Share it on

J Clin Med. 2021 Sep 19;10(18). doi: 10.3390/jcm10184252.

Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program.

Journal of clinical medicine

Pedro Luis Cepas-Guillen, Juan Carlos de la Fuente Mancera, Joan Guzman Bofarull, Marta Farrero, Ander Regueiro, Salvatore Brugaletta, Cristina Ibañez, Laura Sanchis, Marta Sitges, Manel Sabate, Xavier Freixa

Affiliations

  1. Cardiology Department, Cardiovascular Institute (ICCV), Hospital Clinic, IDIBAPS, University of Barcelona, 08036 Barcelona, Spain.
  2. Anesthesiology Department, Hospital Clinic, IDIBAPS, University of Barcelona, 08036 Barcelona, Spain.

PMID: 34575362 PMCID: PMC8471561 DOI: 10.3390/jcm10184252

Abstract

Transcatheter tricuspid valve repair (TTVr) has emerged as an alternative for the treatment of severe tricuspid regurgitation (TR). We report our initial experience with an edge-to-edge TTVr system in a high-volume institution.

METHODS: We included consecutive patients who underwent edge-to-edge TTVr systems. The primary efficacy endpoint was a reduction in the TR of at least one grade. The primary safety endpoint was procedure-related clinical serious adverse events.

RESULTS: A total of 28 patients underwent TTVr with edge-to-edge systems. All patients presented with at least severe TR with a high impact on quality of life (82% of patients in NYHA class ≥ III). The Triclip system was the most used device (89%). The primary efficacy endpoint was met in all patients. Only one patient experienced a procedural complication (femoral pseudoaneurysm). At three-month follow-up, 83% of patients were in NYHA I or II (18% baseline vs. 83% 3 months follow-up;

CONCLUSIONS: Edge-to-edge TTVr systems seem to represent a very valid alternative to prevent morbidity and mortality associated with TR as depicted by the favorable efficacy and safety.

Keywords: heart failure; transcatheter valve repair; tricuspid regurgitation

References

  1. JACC Cardiovasc Imaging. 2019 Mar;12(3):491-499 - PubMed
  2. Front Cardiovasc Med. 2020 Aug 13;7:139 - PubMed
  3. Eur Heart J. 2017 Sep 21;38(36):2739-2791 - PubMed
  4. Circulation. 2021 Feb 2;143(5):e72-e227 - PubMed
  5. Interv Cardiol Clin. 2018 Jan;7(1):37-45 - PubMed
  6. JACC Cardiovasc Imaging. 2019 Apr;12(4):605-621 - PubMed
  7. Lancet. 2019 Nov 30;394(10213):2002-2011 - PubMed
  8. Circ Cardiovasc Imaging. 2017 Jan;10(1): - PubMed
  9. JACC Cardiovasc Imaging. 2014 Dec;7(12):1185-94 - PubMed
  10. Am J Cardiol. 2020 Nov 15;135:84-90 - PubMed
  11. JACC Cardiovasc Interv. 2019 Jan 28;12(2):155-165 - PubMed
  12. JACC Cardiovasc Interv. 2019 Aug 12;12(15):1451-1461 - PubMed
  13. J Am Coll Cardiol. 2021 Jan 26;77(3):229-239 - PubMed
  14. J Am Coll Cardiol. 2013 Mar 26;61(12):1259-67 - PubMed
  15. Eur Heart J Cardiovasc Imaging. 2017 Dec 1;18(12):1342-1343 - PubMed
  16. EuroIntervention. 2018 Aug 20;14(6):645-653 - PubMed
  17. JACC Cardiovasc Interv. 2019 Aug 12;12(15):1423-1434 - PubMed
  18. JACC Heart Fail. 2020 Apr;8(4):265-276 - PubMed
  19. J Am Coll Cardiol. 2017 Dec 19;70(24):2953-2960 - PubMed
  20. Ann Thorac Surg. 2018 Jul;106(1):129-136 - PubMed
  21. EuroIntervention. 2021 Aug 06;17(5):e441-e442 - PubMed
  22. EuroIntervention. 2018 Aug 31;14(AB):AB101-AB111 - PubMed

Publication Types